ELAVL2 and Alzheimer disease: Our results demonstrate that sustained upregulation of MANF contributes to synaptic loss in AD mice by affecting ELAVL2 mediated post-transcriptional program, and indicate that lowering MANF expression could be exploited as a potential therapeutic approach to alleviate the synaptic pathology in AD.